US FDA has approved the world's first RSV vaccine

A vaccine for respiratory syncytial virus (RSV) has been approved by the US Food and Drug Administration, a disease that causes the deaths of numerous Americans each year. Before it can be made available to the general public, the vaccine must first receive approval from the US Centers for Disease Control and Prevention. The manufacturer GSK has named the vaccine Arexvy, and officials are hailing it as a significant breakthrough that could save numerous lives.

It is expected to be accessible to those over 60 years of age within a matter of months.RSV is a respiratory illness that typically results in cold-like symptoms for adults but can pose a danger to young children, the elderly, and individuals with underlying health conditions. According to the CDC, it causes the deaths of 100-300 children under the age of 5 in the US annually.
Annually, it is responsible for the deaths of approximately 6,000 to 10,000 adults over 65 and results in 60,000 to 120,000 hospital admissions.
In severe cases, RSV can cause bronchiolitis, characterized by an accumulation of inflammation in the lungs and breathing difficulties. The vaccine, which took over 60 years to develop, is the first to gain approval for preventing RSV anywhere in the world.